{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:55:42Z","timestamp":1788609342332,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013711","name":"Bayer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006126","name":"Hospital for Sick Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jcjo.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T22:38:52Z","timestamp":1659739132000},"page":"553-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience"],"prefix":"10.1016","volume":"58","author":[{"given":"Maram","family":"Isaac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6738-7807","authenticated-orcid":false,"given":"Kamiar","family":"Mireskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fallaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis H.","family":"Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-3531","authenticated-orcid":false,"given":"Eileen","family":"Javidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6768-3916","authenticated-orcid":false,"given":"Sarah","family":"Chorfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Superstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-6117","authenticated-orcid":false,"given":"Patrick","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin N.","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2022.07.001_bib0001","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.survophthal.2020.12.002","article-title":"Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3701 eyes","volume":"66","author":"Popovic","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0002","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0003","doi-asserted-by":"crossref","first-page":"88e1","DOI":"10.1016\/j.jaapos.2018.10.013","article-title":"Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP","volume":"23","author":"Anand","year":"2019","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4565216","article-title":"Refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab: a clinical study of correction at three years of age","volume":"2018","author":"Chen","year":"2018","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0005","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes","volume":"28","author":"Chen","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0006","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0007","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0008","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaapos.2015.01.009","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0009","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","article-title":"Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"2","author":"Roohipoor","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0010","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0012","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0013","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/eye.2015.289","article-title":"Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up","volume":"30","author":"Isaac","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0014","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0016","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ophtha.2016.04.024","article-title":"Does bevacizumab alter vascularization potential in retinopathy of prematurity?","volume":"123","author":"Isaac","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0017","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0018","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","author":"Henaine-Berra","year":"2014","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0019","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3341\/kjo.2019.0011","article-title":"Refractive outcomes of 4-year-old children after intravitreal anti-vascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity","volume":"33","author":"Kang","year":"2019","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3928\/23258160-20200228-07","article-title":"Functional and morphologic findings at four years after intravitreal bevacizumab or laser for type 1 ROP","volume":"51","author":"Lepore","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0022","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5-year follow-up","volume":"109","author":"O'Keeffe","year":"2016","journal-title":"Ir Med J"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0023","doi-asserted-by":"crossref","first-page":"149e1","DOI":"10.1016\/j.jaapos.2020.03.003","article-title":"Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity","volume":"24","author":"Rodriguez","year":"2020","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0024","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jcjo.2015.10.004","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: considerations for informed consent","volume":"50","author":"Mireskandari","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0025","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Early Treatment for Retinopathy of Prematurity Cooperative Group, Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0026","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study","volume":"128","author":"Good","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0027","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaapos.2021.02.004","article-title":"Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report","volume":"25","author":"Taylor","year":"2021","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0028","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ophtha.2018.12.012","article-title":"Laser treatment for retinopathy of prematurity: a decade since ETROP","volume":"126","author":"Emami","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0029","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/09273972.2016.1159232","article-title":"Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Gunay","year":"2016","journal-title":"Strabismus"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0030","first-page":"135","article-title":"Review of effects of anti-VEGF treatment on refractive error","volume":"8","author":"Mintz-Hittner","year":"2016","journal-title":"Eye Brain"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0031","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archopht.116.3.329","article-title":"Strabismus in premature infants in the first year of life. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"116","author":"Bremer","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0032","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaapos.2011.07.017","article-title":"Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"15","author":"VanderVeen","year":"2011","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0033","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archopht.124.6.766","article-title":"Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity study","volume":"124","author":"VanderVeen","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0034","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bjo.83.5.514","article-title":"Risk factors for strabismus in children born before 32 weeks\u2019 gestation","volume":"83","author":"Pennefather","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.07.001_bib0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jcjo.2020.10.007","article-title":"Binocularity outcomes following treatment for retinopathy of prematurity","volume":"56","author":"Manuchian","year":"2021","journal-title":"Can J Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418222002150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418222002150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:24:15Z","timestamp":1762104255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418222002150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0008418222002150"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.07.001","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}